Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -1.08% is 87% above its 5-year average of -8.08%, near the high end of its 5-year range (-17.41%–3.88%).
As of the fiscal period ended Tuesday, June 30, 2026. 86.93% above its 12-month average of -8.24%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2026 (2026-06-30): -1.08%.
RETURN ON EQUITY (ROE)
-1.08%
RETURN ON EQUITY (ROE) AVG TTM
-8.24%
RETURN ON EQUITY (ROE) AVG 3Y
-9.93%
RETURN ON EQUITY (ROE) AVG 5Y
-8.08%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+86.93%
CURRENT VS 3Y AVG
+89.15%
CURRENT VS 5Y AVG
+86.68%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.30%
median of 610 covered companies
CURRENT VS SECTOR MEDIAN
+97.33%
vs the sector median at left
Innovage Holding Corp.
Market Cap
$1.22B
Return on Equity (ROE)
-1.08%
TTM Avg
-8.24%
3Y Avg
-9.93%
5Y Avg
-8.08%
Market Cap
$1.22B
Return on Equity (ROE)
N/A
TTM Avg
-23.25%
3Y Avg
-1.69%
5Y Avg
10.61%
Market Cap
$1.23B
Return on Equity (ROE)
1.70%
TTM Avg
-39.25%
3Y Avg
-48.34%
5Y Avg
-48.34%
Market Cap
$1.23B
Return on Equity (ROE)
6.53%
TTM Avg
1.49%
3Y Avg
-4.63%
5Y Avg
-8.73%
Market Cap
$1.24B
Return on Equity (ROE)
-36.81%
TTM Avg
-43.14%
3Y Avg
-42.82%
5Y Avg
-37.59%
Market Cap
$1.16B
Return on Equity (ROE)
-17.40%
TTM Avg
-189.25%
3Y Avg
-172.42%
5Y Avg
-134.67%
Market Cap
$1.16B
Return on Equity (ROE)
-50.93%
TTM Avg
-117.72%
3Y Avg
-113.46%
5Y Avg
-86.51%
Market Cap
$1.15B
Return on Equity (ROE)
2.51%
TTM Avg
3.60%
3Y Avg
0.50%
5Y Avg
-7.05%
Market Cap
$1.30B
Return on Equity (ROE)
N/A
TTM Avg
76.67%
3Y Avg
76.67%
5Y Avg
76.67%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Innovage Holding Corp. (INNV) | $1.22B | -1.08% | -8.24% | -9.93% | -8.08% |
| MannKind Corporation (MNKD)vs › | $1.22B | N/A | -23.25% | -1.69% | 10.61% |
| Omada Health (OMDA)vs › | $1.23B | 1.70% | -39.25% | -48.34% | -48.34% |
| Cronos Group Inc. (CRON)vs › | $1.23B | 6.53% | 1.49% | -4.63% | -8.73% |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.24B | -36.81% | -43.14% | -42.82% | -37.59% |
| Nektar Therapeutics (NKTR)vs › | $1.16B | -17.40% | -189.25% | -172.42% | -134.67% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.16B | -50.93% | -117.72% | -113.46% | -86.51% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.15B | 2.51% | 3.60% | 0.50% | -7.05% |
| Kardigan, Inc. (KARD)vs › | $1.30B | N/A | 76.67% | 76.67% | 76.67% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.15B | N/A | 35.70% | 35.70% | 35.70% |
ROE
-1.1%
ROA
-0.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -1.08% |
| 2026-03-31 | -9.69% |
| 2025-12-31 | -1.60% |
| 2025-09-30 | -11.41% |
| 2025-06-30 | -17.41% |
| 2025-03-31 | -13.12% |
| 2024-12-31 | -10.36% |
| 2024-09-30 | -6.12% |
| 2024-06-30 | -7.92% |
| 2024-03-31 | -10.96% |
| 2023-12-31 | -11.05% |
| 2023-09-30 | -13.20% |
| 2023-06-30 | -15.11% |
| 2023-03-31 | -13.78% |
| 2022-12-31 | -12.32% |
| 2022-09-30 | -8.51% |
| 2022-06-30 | -1.96% |
| 2022-03-31 | 3.68% |
| 2021-12-31 | 1.45% |
| 2021-09-30 | 3.88% |
| 2021-06-30 | -13.15% |
| 2021-03-31 | -11.69% |
